Grammatikakis Ι, Εvagelinakis ΕN, Salamalekis N, Κassanos D
3rd Department of Obstetrics and Gynecology, University of Athens, Attiko hospital, Athens, Greece
Correspondence: Evagelinakis N, 3rd Department of Obstetrics and Gynecology, University of Athens, Attiko hospital, 1 Rimini St, GR-12464 Αthens, Greece, E-mail: evangelinakisnikos@yahoo.gr
Abstract
Antiphospholipid syndrome is a condition characterized by one or more episodes of thrombosis in combination with high blood levels of antiphospholipid antibodies. Antiphospholipid syndrome is one of the few treatable causes of pregnancy loss, when early detected. Heparin, usually combined with low-dose aspirin, is used in patients at risk for thrombosis. Pregnancy in women with antiphospholipid syndrome is associated with increased rates of preeclampsia, placental insufficiency, and preterm delivery. Recent studies indicate that women at low risk for thrombosis may be treated with low-dose aspirin. However, remaining controversies and unanswered questions in the field of antiphospholipid syndrome are a source of clinical confusion. This review highlights the most important controversies, taking into account the results of recent obstetric treatment trials and our own clinical experience.
Keywords: antiphospholipid syndrome, pregnancy
p. 109-117